A comprehensive living network meta-analysis evaluated the safety and efficacy of 39 treatment regimens for moderate to severe hidradenitis suppurativa, drawing from 25 randomized clinical trials with 5,767 participants. The study used the Hidradenitis Suppurativa Clinical Response (HiSCR) to measure outcomes, finding that sonelokimab 120 mg every 4 weeks had the highest effectiveness. Other notable treatments included lutikizumab and adalimumab. Although newer treatments showed promising results, no significant superiority over adalimumab was established, highlighting the need for larger trials to confirm these findings for better clinical decisions.

Source: JAMA Dermatology